i would also point out that market share of new to brand scripts by urologists/endocrinologists is already up to 29% (source below).
on this measure Axiron has overtaken all the other competitors except for Androgel, however that can't be far away as Androgel has fallen to 34% from almost 60% in the (only) 3mths since Axiron was launched!
as mentioned in my last post, i think sales performance and potential for takeover by eli lilly will be the key drivers for this stock: sales are exceeding my expectations and in my mind this increases potential for takeover.
also positive to hear that regulatory updates for entry of Axiron to europe and other markets are coming up
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)